as of 10-01-2026 4:00pm EST
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 25.7M | IPO Year: | 2003 |
| Target Price: | N/A | AVG Volume (30 days): | 884.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | quarterly |
| EPS: | -2.06 | EPS Growth: | 13.81 |
| 52 Week Low/High: | $0.69 - $2.97 | Next Earning Date: | 09-28-2026 |
| Revenue: | N/A | Revenue Growth: | -100.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.83 | Index: | N/A |
| Free Cash Flow: | -9121000.0 | FCF Growth: | N/A |
SEC 8-K filings with transcript text
Jul 30, 2026
May 13, 2026
Feb 17, 2026
See how LITS stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "LITS Lite Strategy Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.